Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.43 |
| ▸ | CDK1 | P06493 | 5/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.43 |
| ▸ | CDK4 | P11802 | 4/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.43 |
| ▸ | CDK9 | P50750 | 3/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | CDK7 | P50613 | 2/20 | 0.43 |
| ▸ | CCNH | P51946 | 2/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | MARK3 | P27448 | 1/20 | 0.41 |
| ▸ | STK3 | Q13188 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13756756 | 0.88 | PTGS2 (0.48) | CDK2CDK1CCNB1CDK4CCNE1 | |
| SCHEMBL13756693 | 0.88 | PTGS2 (0.47) | CDK2CDK1CCNB1CDK4CCNE1 | |
| SCHEMBL13756691 | 0.86 | AURKA (0.54) | CDK4AURKAPTK2JAK2JAK3 | |
| SCHEMBL13756753 | 0.86 | FGFR4 (0.50) | CDK5CDK5R1PTGS2MAPTPTK2 | |
| SCHEMBL13756846 | 0.85 | CDK2 (0.44) | CDK2CDK1CCNB1CDK4CCNE1 | |
| SCHEMBL13756828 | 0.83 | TTK (0.53) | STAT6PTK2JAK2JAK3KCNH2 | |
| SCHEMBL13756755 | 0.81 | PTK2 (0.48) | CDK2CDK5CDK5R1CCNA2MAPT | |
| SCHEMBL13756752 | 0.81 | BRD4 (0.49) | PTGS1PTGS2MAPT | |
| SCHEMBL13756751 | 0.80 | JAK2 (0.43) | CDK2CDK1CCNB1CDK4CCNE1 | |
| SCHEMBL13756800 | 0.79 | CDK2 (0.46) | CDK2CDK1CCNB1CDK4CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | CDK2 77/4885CDK1 89/4885CCNB1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.